Literature DB >> 24705066

Dosimetric perturbations of a lead shield for surface and interstitial high-dose-rate brachytherapy.

Cristian Candela-Juan1, Domingo Granero, Javier Vijande, Facundo Ballester, Jose Perez-Calatayud, Mark J Rivard.   

Abstract

In surface and interstitial high-dose-rate brachytherapy with either (60)Co, (192)Ir, or (169)Yb sources, some radiosensitive organs near the surface may be exposed to high absorbed doses. This may be reduced by covering the implants with a lead shield on the body surface, which results in dosimetric perturbations. Monte Carlo simulations in Geant4 were performed for the three radionuclides placed at a single dwell position. Four different shield thicknesses (0, 3, 6, and 10 mm) and three different source depths (0, 5, and 10 mm) in water were considered, with the lead shield placed at the phantom surface. Backscatter dose enhancement and transmission data were obtained for the lead shields. Results were corrected to account for a realistic clinical case with multiple dwell positions. The range of the high backscatter dose enhancement in water is 3 mm for (60)Co and 1 mm for both (192)Ir and (169)Yb. Transmission data for (60)Co and (192)Ir are smaller than those reported by Papagiannis et al (2008 Med. Phys. 35 4898-4906) for brachytherapy facility shielding; for (169)Yb, the difference is negligible. In conclusion, the backscatter overdose produced by the lead shield can be avoided by just adding a few millimetres of bolus. Transmission data provided in this work as a function of lead thickness can be used to estimate healthy organ equivalent dose saving. Use of a lead shield is justified.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24705066     DOI: 10.1088/0952-4746/34/2/297

Source DB:  PubMed          Journal:  J Radiol Prot        ISSN: 0952-4746            Impact factor:   1.394


  2 in total

1.  Recommendations of the Spanish brachytherapy group (GEB) of Spanish Society of Radiation Oncology (SEOR) and the Spanish Society of Medical Physics (SEFM) for high-dose rate (HDR) non melanoma skin cancer brachytherapy.

Authors:  S Rodríguez; M Arenas; C Gutierrez; J Richart; J Perez-Calatayud; F Celada; M Santos; A Rovirosa
Journal:  Clin Transl Oncol       Date:  2017-08-14       Impact factor: 3.405

2.  Testicular shielding in penile brachytherapy.

Authors:  Arpita Bindal; Umesh Mahantshetty; Chandrashekhar M Tambe; Yogesh Ghadi; Vedang Murthy; Shyam Kishore Shrivastava
Journal:  J Contemp Brachytherapy       Date:  2015-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.